Results of antiviral therapy of viral respiratory infection in selected groups of patients

The aim is to substantiate the need and evaluate the effectiveness of inosine pranobex therapy for viral respiratory infections in patients with psychiatric pathology. Materials and methods. At stage 1, 59 patients with a background of manifestations of schizophrenia or schizotypal disorder were included in the retrospective study, in whom repeated viral respiratory infection was observed. The main group included 27 patients who received inosine pranobex (Groprinosin), and in the comparison group 32 patients were treated for viral respiratory infections with other drugs. At stage 2, 210 tissue samples of deceased patients with parkinsonism (15), schizophrenia or hallucinosis (15) or in the absence of these pathologies (12) were examined for the presence of herpes viruses. Results. In the group treated with inosine pranobex, the period of viral respiratory infection was 6.3±1.63, and with other therapy – 7.8±2.78 days. Complications in the main group were noted in 7%, and in the comparison group – in 28%. Inosine pranobex therapy was accompanied by an improvement in the course of psychiatric pathology. Viruses were most often detected in patients with schizophrenia and hallucinosis: HHV-6 DNA in 29 samples (39%) obtained from13 patients (87%), cytomegalovirus (CMV) DNA in 7 (47%) patients in 11 samples (15%), Epstein-Barr virus (EBV) in 5 patients (33%) in 10 samples (13%), more often in kidney samples. Conclusions. Inosine pranobex (Groprinosine) reduces the course of viral respiratory infections by 1.5 days, reduces the frequency of complications by 4 times, reduces the frequency of repeated episodes of viral respiratory infections by 3 times, reduces the frequency and severity of relapses of schizophrenia and schizotypal disorders. The necessity to use an effective antiviral and immunomodulatory drug is confirmed by more frequent detection of HHV-6 and CMV DNA in organs, more often in the kidneys, in patients with schizophrenia and hallucinosis.

Authors

Publication Details

Journal
Immunopathology Allergology Infectology
Published
2024-10-01
DOI
https://doi.org/10.14427/jipai.2024.4.6
Primary Topic
Immunodeficiency and Autoimmune Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Results of antiviral therapy of viral respiratory infection in selected groups of patients

Т. А. Руженцова, Д. А. Хавкина, I.N. Khalyastov, Valeria V. Orlova et al.
Immunopathology Allergology Infectology
Immunodeficiency and Autoimmune Disorders
article

Results of antiviral therapy of viral respiratory infection in selected groups of patients

Т. А. Руженцова, Д. А. Хавкина, I.N. Khalyastov, Valeria V. Orlova, O. Yu. Borisova, A.D. Voropaev, Ирина Иосифовна Михайлова, Александр Гарбузов, A. А. Kanibolotskiy, N Kaluzhnaya
article en

Abstract

The aim is to substantiate the need and evaluate the effectiveness of inosine pranobex therapy for viral respiratory infections in patients with psychiatric pathology. Materials and methods. At stage 1, 59 patients with a background of manifestations of schizophrenia or schizotypal disorder were included in the retrospective study, in whom repeated viral respiratory infection was observed. The main group included 27 patients who received inosine pranobex (Groprinosin), and in the comparison group 32 patients were treated for viral respiratory infections with other drugs. At stage 2, 210 tissue samples of deceased patients with parkinsonism (15), schizophrenia or hallucinosis (15) or in the absence of these pathologies (12) were examined for the presence of herpes viruses. Results. In the group treated with inosine pranobex, the period of viral respiratory infection was 6.3±1.63, and with other therapy – 7.8±2.78 days. Complications in the main group were noted in 7%, and in the comparison group – in 28%. Inosine pranobex therapy was accompanied by an improvement in the course of psychiatric pathology. Viruses were most often detected in patients with schizophrenia and hallucinosis: HHV-6 DNA in 29 samples (39%) obtained from13 patients (87%), cytomegalovirus (CMV) DNA in 7 (47%) patients in 11 samples (15%), Epstein-Barr virus (EBV) in 5 patients (33%) in 10 samples (13%), more often in kidney samples. Conclusions. Inosine pranobex (Groprinosine) reduces the course of viral respiratory infections by 1.5 days, reduces the frequency of complications by 4 times, reduces the frequency of repeated episodes of viral respiratory infections by 3 times, reduces the frequency and severity of relapses of schizophrenia and schizotypal disorders. The necessity to use an effective antiviral and immunomodulatory drug is confirmed by more frequent detection of HHV-6 and CMV DNA in organs, more often in the kidneys, in patients with schizophrenia and hallucinosis.

Immunopathology Allergology Infectology
Openalex Percentile: Top 68%
Immunodeficiency and Autoimmune Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.